Millennium Management
UNCY icon

Millennium Management’s Unicycive Therapeutics UNCY Stock Holding History

Millennium Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Sell
271,456
-1,127,892
-81% -$8.32M ﹤0.01% 4161
2026
Q1 		$9.21M Buy
1,399,348
+384,505
+38% +$2.52M ﹤0.01% 2250
2025
Q4 		$5.86M Buy
+1,014,843
New +$5.42M ﹤0.01% 2834

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Millennium Management's UNCY Position: Q2 2026 in Review

Millennium Management reduced its Unicycive Therapeutics (UNCY) stake by 81% in Q2 2026, selling an estimated $8.32M and leaving 271,456 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #4161.

Millennium Management first reported a position in UNCY in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.21M in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Millennium Management held 271,456 shares of Unicycive Therapeutics worth $1.27M as of Q2 2026.
  • Millennium Management sold 1,127,892 Unicycive Therapeutics shares in Q2 2026, an estimated $8.32M.
  • Unicycive Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #4161 holding.
  • Millennium Management first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Millennium Management's Unicycive Therapeutics position peaked at $9.21M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.